These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15667906)

  • 1. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
    Altundag K; Altundag O; Morandi P; Gunduz M
    Urology; 2005 Jan; 65(1):211-2; author reply 212. PubMed ID: 15667906
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer.
    Mathew P; Fidler IJ; Logothetis CJ
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):24-9. PubMed ID: 15176001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases.
    Mathew P; Wen S; Morita S; Thall PF
    J Interferon Cytokine Res; 2011 Jul; 31(7):539-44. PubMed ID: 21323568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.
    Lipton A; Campbell-Baird C; Harvey H; Kim C; Demers L; Costa L
    Am J Clin Oncol; 2010 Feb; 33(1):75-8. PubMed ID: 19652577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
    Tiffany NM; Wersinger EM; Garzotto M; Beer TM
    Urology; 2004 May; 63(5):934-9. PubMed ID: 15134984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    Kim SJ; Uehara H; Yazici S; Busby JE; Nakamura T; He J; Maya M; Logothetis C; Mathew P; Wang X; Do KA; Fan D; Fidler IJ
    J Natl Cancer Inst; 2006 Jun; 98(11):783-93. PubMed ID: 16757703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Hofer MD; Rubin MA
    J Clin Oncol; 2005 Feb; 23(6):1332-3; author reply 1333-4. PubMed ID: 15718346
    [No Abstract]   [Full Text] [Related]  

  • 10. Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
    Joensuu TK
    Urol Int; 2008; 80(4):448-50. PubMed ID: 18587260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
    Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
    Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
    Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
    Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
    Mathew P; Thall PF; Bucana CD; Oh WK; Morris MJ; Jones DM; Johnson MM; Wen S; Pagliaro LC; Tannir NM; Tu SM; Meluch AA; Smith L; Cohen L; Kim SJ; Troncoso P; Fidler IJ; Logothetis CJ
    Clin Cancer Res; 2007 Oct; 13(19):5816-24. PubMed ID: 17908974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.
    Kim JH; Song M; Kang GH; Lee ER; Choi HY; Lee C; Kim JH; Kim Y; Koo BN; Cho SG
    Leuk Res; 2012 Sep; 36(9):1157-64. PubMed ID: 22770910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL; Wu S; Arlen PM; Dahut WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
    Lin AM; Rini BI; Derynck MK; Weinberg V; Park M; Ryan CJ; Rosenberg JE; Bubley G; Small EJ
    Clin Genitourin Cancer; 2007 Jun; 5(5):323-8. PubMed ID: 17645829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
    Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
    Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
    Santini D; Vincenzi B; Tonini G; Scarpa S; Baldi A
    Clin Cancer Res; 2003 Aug; 9(8):3215; author reply 3216. PubMed ID: 12912976
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
    Corcoran NM; Costello AJ
    BJU Int; 2005 Sep; 96(4):640-6. PubMed ID: 16104925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.